The team focused on a population they had previously identified, marked by the co-expression of the surface proteins CD34, CD123, CD25 and CD99. In their earlier work, these CD34/CD123/CD25/CD99-positive leukemic progenitor cells (LPCs) were seen to persist in patients after induction chemotherapy and to herald disease recurrence in FLT3-ITD-mutated AML. What remained unclear was whether these cells were merely passive survivors or genuine leukemia-initiating cells with stem-like capacity. The new study answers that question directly, providing what the authors describe as the first functional evidence that FLT3-ITD-mutated LPCs maintain stem cell potential in vivo.

The clinical part of the investigation began with a diagnostic twist that could change practice. Using multiparametric flow cytometry on prospective patient samples, the researchers showed that when the CD34/CD123/CD25/CD99-positive fraction exceeds 7.4 percent of the relevant cell compartment, the presence of an FLT3-ITD mutation can be predicted with 88.2 percent sensitivity and, remarkably, 100 percent specificity. In other words, an immunophenotypic signature visible on a standard flow cytometry panel can act as a surrogate flag for the mutation, and the same signature can be tracked over time as a form of measurable residual disease (MRD) monitoring that does not depend on molecular assays alone.

To test whether these cells truly behave like leukemia stem cells, the team purified LPCs by cell sorting and transplanted them into conditioned NSG mice, an immunodeficient strain widely used for human hematopoietic engraftment studies. The sorted LPCs engrafted efficiently and reinitiated leukemia in the recipient animals. Critically, when the resulting leukemic cells were harvested and transplanted into successive cohorts of mice, the LPC compartment expanded with each sequential passage. This serial transplantation behavior, with the progenitor pool growing rather than exhausting, is exactly what would be expected from a self-renewing disease reservoir capable of sustaining relapse.

With the functional identity of the LPCs established, the researchers turned to molecular profiling to understand what makes them tick. They performed transcriptomic analysis on 13 paired samples of LPCs and leukemic blasts from the same patients, allowing a direct comparison between the progenitor population and the bulk tumor cells. The most striking finding was an upregulation of genes encoding protein kinases in the LPCs, with the lymphocyte-specific protein tyrosine kinase, known as LCK, standing out as the dominant signal. LCK is classically associated with T-cell receptor signaling, so its prominence in myeloid leukemic progenitors was unexpected and immediately suggested a druggable vulnerability.

The LCK finding was not a one-off artifact of a small cohort. The team went on to confirm elevated LCK expression in 28 additional FLT3-ITD-mutated AML samples, consolidating the observation across an independent validation set. This reproducibility matters, because candidate therapeutic targets in AML have a long history of failing to survive independent validation. Here, the kinase overexpression pattern appeared consistently in the very cells that seed relapse, not just in the bulk blast population that most genomic studies interrogate.

On the therapeutic side, the researchers examined how the FLT3 inhibitor gilteritinib, already approved for relapsed or refractory FLT3-mutated AML, affects these progenitor cells. Gilteritinib reduced proliferation and dampened the FLT3-STAT5 signaling pathway, a canonical downstream axis of the mutant receptor, in both FLT3-ITD-mutated blasts and LPCs. That the drug reaches its canonical target even within the stem-like compartment is encouraging, but the experiments also revealed why single-agent inhibition is not enough: the LPCs retained survival capacity, pointing to parallel signaling routes that keep the cells alive when FLT3 itself is blocked.

That parallel route appears to run through LCK. When the investigators added LCK inhibition on top of gilteritinib, the effects were more than additive in key respects. Dual blockade further attenuated FLT3/STAT5 activity, disrupted the aberrant subcellular localization of the FLT3 receptor, and downregulated ABC transporter-associated multidrug resistance, the family of efflux pumps that chemotherapy and targeted agents alike must overcome. The combination of gilteritinib with LCK blockade enhanced the overall anti-leukemic activity, consistent with the idea that FLT3 and LCK cooperate to sustain FLT3-ITD-mutated leukemic progenitors and that hitting both pathways simultaneously collapses their support network.

The mechanistic detail about FLT3 localization deserves particular attention. The biosynthetic trafficking of FLT3-ITD has been implicated in the mutant receptor’s ability to transduce autonomous growth signals from intracellular compartments, and the finding that LCK inhibition corrects aberrant FLT3 localization suggests that LCK may help position the mutant receptor where it can signal most effectively. Meanwhile, the suppression of ABC transporter expression links the LCK axis to one of the classic mechanisms of chemoresistance in AML, offering a potential explanation for why LPCs survive induction chemotherapy in the first place.

Taken together, the study delivers three practical takeaways. First, a defined immunophenotypic signature above a 7.4 percent threshold provides a clinically actionable tool for identifying FLT3-ITD-mutated disease and monitoring residual leukemic progenitors by flow cytometry. Second, the in vivo engraftment and serial passage data cement LPCs as the functional reservoir of relapse, making them the logical target for eradication strategies aimed at long-term remission. Third, the LCK pathway emerges as a novel molecular vulnerability that can be attacked in combination with existing FLT3 inhibitors, a strategy the authors argue could selectively eliminate residual FLT3-ITD-mutated LPCs and improve long-term outcomes in a disease where relapsed and refractory cases remain a pressing unmet medical need. As gilteritinib-resistant relapses continue to challenge clinicians, the prospect of pairing FLT3 blockade with LCK-directed agents gives the field a concrete, mechanistically grounded next step.

Subject of Research: Functional and molecular characterization of FLT3-ITD-mutated leukemic progenitor cells in acute myeloid leukemia

Article Title: Characterization of FLT3-ITD-mutated leukemic stem cells: functional and clinical insights

Article References: Travaglini, S., Ottone, T., Antonelli, S., Serra, M., Silvestrini, G., Masciarelli, S., Sniegocka, M., Noguera, N. I., De Bardi, M., Lomi, M., Consalvo, M. A. I., Gurnari, C., Piazza, R., Divona, M., Marchesi, F., Fazi, F., Mattei, M., Buccisano, F., Battistini, L., … Voso, M. T. (2026). Characterization of FLT3-ITD-mutated leukemic stem cells: functional and clinical insights. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03319-0

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03319-0

Keywords: acute myeloid leukemia, FLT3-ITD, leukemic stem cells, leukemic progenitor cells, gilteritinib, LCK, STAT5 signaling, measurable residual disease, flow cytometry, NSG mice, drug resistance, relapse

The central problem the researchers set out to solve is well known to anyone following the CAR-T field. Engineered T cells have produced remarkable results in certain blood cancers, but solid tumors present a hostile microenvironment that wears these cells down. In pancreatic cancer specifically, mesothelin-targeted CAR-T therapy—a promising approach because mesothelin is abundantly expressed on pancreatic tumor cells—has been limited by insufficient persistence, progressive T-cell exhaustion, and metabolic dysfunction. CAR-T cells that enter the tumor find themselves starved of nutrients, bathed in suppressive signals, and deprived of the cytokine support they need to keep proliferating and killing. Within days, many of them become dysfunctional ghosts of their former selves.

Interleukin-2 is the classic T-cell growth cytokine, and systemic administration of recombinant IL-2 has long been known to boost T-cell responses. But giving IL-2 intravenously at doses high enough to support CAR-T cells triggers severe toxicity, including vascular leak syndrome and dangerous expansion of regulatory T cells, which paradoxically suppress antitumor immunity. The study’s solution is elegant in its localization: the team engineered second-generation MSLN-targeted CAR-T cells to secrete an IgG1 Fc-fused IL-2(C125S) variant, creating what they call MSLN-IL2m CAR-T cells. The Fc fusion extends the cytokine’s half-life, while the C125S mutation disables a site associated with preferential expansion of regulatory T cells, aiming the growth signal preferentially at the CAR-T cells themselves rather than at their suppressive counterparts.

The experimental design was deliberately rigorous. The researchers generated CAR-T cells from five independent healthy donors, ensuring that their findings were not an artifact of a single donor’s immune system. They tested these cells against pancreatic ductal adenocarcinoma cell lines expressing different levels of mesothelin, subjected them to serial antigen-stimulation assays that mimic the repeated encounters CAR-T cells face inside a tumor, and challenged them with suppressive-stress models designed to reproduce the hostile conditions of the pancreatic tumor microenvironment. Phenotypic and functional analyses tracked exhaustion markers and memory phenotypes, while metabolic-flux assays measured the cells’ mitochondrial performance in real time.

The results were striking across the board. MSLN-IL2m CAR-T cells showed enhanced expansion and stronger activation of STAT5, the transcription factor that serves as the primary downstream messenger for the IL-2 receptor, while maintaining CAR expression and viability comparable to conventional cells. When repeatedly stimulated with antigen, the cytokine-secreting cells demonstrated stronger antigen-dependent cytotoxicity, greater proliferation, more robust cytokine production, and markedly better functional persistence. Just as importantly, they displayed reduced expression of exhaustion-associated markers and preserved memory-associated phenotypes—the immunological hallmarks of cells that can keep fighting rather than burn out.

The metabolic findings may be the most novel aspect of the study. Under PDAC-associated suppressive conditions, MSLN-IL2m CAR-T cells maintained greater mitochondrial membrane potential, greater spare respiratory capacity, and higher ATP production than their conventional counterparts. They also expressed higher levels of PPARGC1A, the master regulator of mitochondrial biogenesis, and CPT1A, a key enzyme in fatty acid oxidation, while showing a lower mitochondrial superoxide-associated signal, indicating less oxidative damage. In the metabolic language of modern immunology, these cells remained oxidative, resilient powerhouses instead of collapsing into the glycolytically exhausted state that characterizes dysfunctional tumor-infiltrating T cells.

To confirm that these advantages actually flowed through the IL-2 receptor pathway, the researchers used pharmacological STAT5 inhibition and IL-2Rα blockade. Both interventions partially attenuated the functional, phenotypic, and metabolic advantages of the engineered cells, supporting an important—but notably non-exclusive—contribution of IL-2Rα–STAT5 signaling. This partial dependence suggests that the Fc-fused cytokine may also act through additional mechanisms, such as autocrine and paracrine effects on other IL-2 receptor configurations, and leaves room for further mechanistic dissection in future work.

The in vivo results provided the crucial translational validation. In an AsPC-1 xenograft model of pancreatic cancer, MSLN-IL2m CAR-T cells showed greater intratumoral accumulation, improved tumor control, and reduced bioluminescent tumor burden compared with conventional MSLN CAR-T cells, and the treated animals survived significantly longer. Tolerability assessments revealed no major abnormalities in hepatic, renal, or hematologic parameters, and body weight remained stable—early reassurance that localized cytokine delivery does not reproduce the systemic toxicity that has plagued recombinant IL-2 therapy, though the authors are careful to note that comprehensive safety evaluation remains necessary.

The implications for the field are considerable. Armoring CAR-T cells with autocrine cytokine support has been attempted before, but the specific combination of an Fc fusion for extended half-life and the C125S mutation for reduced regulatory T-cell preference represents a refined iteration of the concept. By coupling the cytokine’s production directly to the CAR-T cells themselves, the approach ensures that the growth signal is delivered exactly where it is needed—at the tumor site, in the midst of antigen stimulation—rather than systemically. The metabolic data add an important dimension, suggesting that the cytokine support does not merely keep cells alive but actively preserves their mitochondrial machinery and oxidative metabolism under stress.

Cautions remain, as they must in any preclinical study. The xenograft model used, while standard for the field, does not fully recapitulate the immunosuppressive complexity of human pancreatic tumors, and the authors explicitly call for validation in clinically relevant models and comprehensive safety assessment before the approach moves toward patients. Questions about the long-term behavior of cytokine-secreting cells, the risk of uncontrolled autonomous growth, and the behavior of the construct in humans all await answers. Still, the study delivers a clear and encouraging message: when CAR-T cells are engineered to carry their own metabolic and survival support into the tumor battlefield, they fight longer, stay fitter, and kill better—a combination that pancreatic cancer patients, who have waited too long for immunotherapy to work for them, will be watching closely.

Subject of Research: Engineering mesothelin-targeted CAR-T cells to secrete Fc-fused IL-2(C125S) to improve persistence and antitumor activity in pancreatic cancer

Article Title: Fc-fused IL-2(C125S) improves MSLN-targeted CAR-T cell persistence, metabolic fitness, and antitumor activity

Article References: Quan, H., Yao, J., Zhang, Y., Zhan, F., & Wang, Y. (2026). Fc-fused IL-2(C125S) improves MSLN-targeted CAR-T cell persistence, metabolic fitness, and antitumor activity. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09016-x

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09016-x

Keywords: CAR-T cells, pancreatic ductal adenocarcinoma, mesothelin, interleukin-2, T-cell exhaustion, mitochondrial fitness, immunometabolism, STAT5 signaling, solid tumors, cytokine delivery, preclinical study, Journal of Translational Medicine